Neurotrophin-targeted therapeutics: A gateway to cognition and more?
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), are small proteins expressed in the brain and peripheral tissues, which regulate several key aspects of neuronal function, including neurogenesis, synaptic plasticity and neuroprotection, but also programmed cell death. This broad range of effects is a result of a complex downstream signaling pathway, with differential spatial and temporal activation patterns further diversifying their physiological effects. Alterations in neurotrophin levels, or known polymorphisms in neurotrophin genes, have been linked to a variety of disorders, including depression and Alzheimer's disease (AD). Historically, their therapeutic potential in these disorders has been hampered by the lack of suitable tool molecules for clinical studies. However, recent advancements have led to the development of new therapeutic candidates, which are now in clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTRand Sortilin
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, R., Chen, Z.-Y., Lee, F. S., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5123-04.2005 · Cited by 1,013
Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Raid, S. W., Blair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90396-g · Cited by 820
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Essential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406
Adachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.019 · Cited by 380
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Rex, C. S., Lin, C.-Y., Kramár, E. A., Chen, L. Y., Gall, C. M., & Lynch, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4037-06.2007 · Cited by 324
Neurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124
Deoxygedunin, a Natural Product with Potent Neurotrophic Activity in Mice
Jang, S.-W., Liu, X., Chan, C. B., France, S. A., Sayeed, I., Tang, W., Lin, X., Xiao, G., Andero, R., Chang, Q., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011528 · Cited by 101
Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
Boltaev, U., Meyer, Y., Tolibzoda, F., Jacques, T., Gassaway, M., Xu, Q., Wagner, F., Zhang, Y.-L., Palmer, M., Holson, E., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal1670 · Cited by 94
Warnault, V., Darcq, E., Morisot, N., Phamluong, K., Wilbrecht, L., Massa, S. M., Longo, F. M., & Ron, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.007 · Cited by 89
Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain · doi:10.1093/brain/aww200 · Cited by 76
Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
TrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45
Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080704 · Cited by 42
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P. (2021) · Cells · doi:10.3390/cells10081871 · Cited by 33
Self-citationVakhitova, Y. V., Kalinina, T. S., Zainullina, L. F., Lusta, A. Y., Volkova, A. V., Kudryashov, N. V., Gudasheva, T. A., Shimshirt, A. A., Kadnikov, I. A., Voronin, M. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413381 · Cited by 21
Cited by
Myokines: Metabolic regulation in obesity and type 2 diabetes
Chen, Z.-T., Weng, Z.-X., Lin, J. D., & Meng, Z.-X. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae006 · Cited by 58
“Brain-derived neurotrophic factor is a member of the neurotro-phins, a small protein produced by neurons [182].”
Interplay between stress, sleep, and BDNF in a high-risk sample of young adults
Varghese, N., Buergin, D., Boonmann, C., Stadler, C., Schmid, M., Eckert, A., & Unternaehrer, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-47726-0 · Cited by 11
Önnestam, K., Nilsson, B., Rother, M., Rein-Hedin, E., Bylund, J., Anderer, P., Kemethofer, M., Halldin, M. M., Sandin, J., & Segerdahl, M. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.89 · Cited by 10
“Targeting the neurotrophin signaling pathways has been challenging due to their complex biology, limiting the attempts to develop therapeutics with this target (27).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Nordvall, G., Forsell, P., & Sandin, J.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 27
- Issue
- 10
- Pages
- 103318
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W4285603011
- Cited by
- 48
- References
- 23
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.